Trial Profile

Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil/amlodipine/hydrochlorothiazide (Primary) ; Olmesartan medoxomil/amlodipine
Indications Essential hypertension
Focus Therapeutic Use
Sponsors Daiichi Sankyo Company

29 Aug 2012 54-Week results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
29 Apr 2012 Analysis comparing efficacy in different age and gender groups presented at the 22nd European Meeting on Hypertension.
29 Apr 2012 Long-term results at 54 weeks presented at the 22nd European Meeting on Hypertension.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com